Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (1112)	10/28/1999 4:38:00 PM
From: Street Walker	Respond to of 5582

Go back to the old KIDE board and see the first discoverers. I really liked what I saw happening in KIDE last November and crunched the numbers, but more importantly, I am blessed with the capability of looking farther out in the future and recognizing a products impact. Its a gift. ZICAM has yet to be recognized (pending second clinicals and advertisements) I am not gifted with processing numbers like Dan, but I just see the long term impact ZICAM will have in the common cold industry that is $2.5 Billion strong. I have personally used Zicam a few times and had tremendous success. Patients, family, friends and friends of those could be all poster childs for ZICAM in treating their colds. Its a wonder product. Just beginning and will penetrate further into the $2.5 Billion market each year. ZICAM is going international. Once again, I don't have the numbers for this, but knowing the common cold is ubiquious to all nations and peoples it is easy for me to visualize that ZICAM will be a huge money maker for years on out. Shorts rely on past statements. Somewhere in their brain chemisty, they lack the ability to see forward. Nicotine Gum: No one knows a lot about this because there has been no formal announcement. All we know is what was said at the Shareholders meeting - GUMM would be involved with an international company. There is the possibility of two types of Nic Gum 1)smoking cessation 2)a smaller dose for those who would like a small amount of nicotine throughout the day or are unable to smoke in certain buildings or meetings. I can't give numbers on revenues of such a product, but I do know that last spring SmithKline Beecham produced around $183 million in their nicorette sales in just one quarter. Its one of their best selling products. SBH will not be able to compete with GUMM. GUMM's specialty chewing/functional gums are the standard. SBH wanted GUMM to produce their nicorette years ago but GUMM uterly refused because sbh wanted all the money. SBH knows GUMM's capabilities and they will be crushed by the taste,texture and price of GUMM's product. In the future, GUMM will be making more money a quarter from their Nic than SBH. Use this information to create your own long term vision. As Bo Didley said, >>No time frame in mind when you're strong and long a stock with a product line up like GUMM.<< Regards, S.W.